Surveillance for pneumococcal disease, Bangladesh: mplications for prevention

Full metadata record
DC FieldValueLanguage
dc.date.accessioned2006-09-19T09:47:19Z-
dc.date.available2006-09-19T09:47:19Z-
dc.date.issued2006-06-
dc.identifier.urihttp://hdl.handle.net/123456789/63-
dc.description.abstractStreptococcus pneumoniae (pneumococcus) is a leading cause of childhood pneumonia worldwide. New, safe effective vaccines have been developed, but the burden of pneumococcus in Bangladesh is unclear. We conducted surveillance for pneumococcus at seven hospitals and two community sites in Bangladesh. Between April 2004 and February 2006 we identified 117 isolates of pneumococcus from blood or cerebrospinal fluid (CSF) culture. All seven hospitals and both community sites identified patients with invasive pneumococcal disease. Most strains (72%) were resistant to co-trimoxazole. Fifty-eight percent of strains identified in community surveillance would be covered by the 9-valent pneumococcal conjugate vaccine. Pneumococcal conjugate vaccine would be expected to meaningfully improve child survival in Bangladesh.en
dc.description.sponsorshipPneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP) at Johns Hopkins Bloomberg School of Public Health with funding through the Global Alliance for Vaccines and Immunisation.en
dc.format.extent115246 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen
dc.relation.ispartofseriesHealth Sci Bullen
dc.relation.ispartofseries2006, 4(2):7-11en
dc.titleSurveillance for pneumococcal disease, Bangladesh: mplications for preventionen
dc.typeArticleen
Appears in Collections:Infectious diseases and vaccine sciences research papers

Files in This Item:
File Description SizeFormat 
001_hsb42Eng_Final_Surveillance.pdf112.54 kBAdobe PDFView/Open


This item is protected by original copyright